Podcasts about Barda

Bir halk neden isyan eder? Aslında herhangi bir sebep olabilir bu. Bardağı taşıran son damla misali… Gezi'de olduğu gibi ağaçların kesilmesine karşı çıkanların çadırlarının yakılması ya da 19 Mart'ta olduğu gibi seçilmiş bir belediye başkanının, müstakbel bir cumhurbaşkanı adayının siyasi bir operasyonla içeri atılması bardağı taşırabilir. Halk sokağa dökülebilir. İktidara bakarsanız bunlar hep dış güçlerin işleridir. Kişi kendinden bilir. Kendileri Amerika'dan aldıkları talimatla hocalarını terk edip yine Amerika'dan aldıkları icazetle iktidar oldukları için kendi iktidarlarını tehlikede gördüklerinde de hemen “dış güçler” diye feryada başlarlar. Oysa her şeyin sebebi kendileridir! Bardak taşınca sadece iktidar halkın karşısına çıkmaz. İktidara karşı olsa da düzene sonuna kadar bağlı olan düzen muhalefeti de rolünü oynamaya başlar. Halkın isyanını soğutur, böler, saptırır. Sebep onlardır, çözüm ise bizdedir. Emekçi halktadır!Emekçi halk kendi gündemine sahip çıkmalı ve bu gündemi siyasetin merkezine taşımalıdır. Çünkü bardağı taşıran son damlanın ne olduğu kadar, bardağın nasıl dolduğu da önemlidir. Türkiye işçi sınıfı için bardak, işsizlik ve yoksulluk ile ağzına kadar dolmuş durumda. Bunun da sebebi iktidarın emperyalist para babalarına, yerli ve yabancı tekellere hizmet eden, sermayeye dost, işçiye düşman politikaları. Ekonomiyi teslim ettikleri İngiliz Mehmet'e (kendisi resmen İngiliz vatandaşıdır) Orta Vadeli Program diye bir kemer sıkma programı hazırlatıp kemeri işçi sınıfının boynuna taktılar, sıktıkça sıkıyorlar.İşte rakamlar! TÜİK'in resmî rakamları ile atıl işgücü oranı yani gerçek işsizlik oranı yüzde 32,1'e ulaştı ve rekor kırdı. Pandemi döneminde dahi bu rakam en fazla yüzde 30'a (Ocak 2021) çıkmıştı. Bugün her üç kişiden biri işsiz! Vestel'in krizin faturasını işçiye çıkartmak için 2.000 işçiyi işten atma planı kamuoyunda ses getirdi. Ancak hâlihazırda sanayide fabrikalar onar onar, yüzer yüzer işçi çıkartıyor. İşsizler ordusu büyüdükçe patronlar işten çıkarma tehdidiyle çalışanlar üzerinde terör estiriyor. Çıkartılan işçiler yeniden iş bulmakta zorlanıyor. Bir şekilde iş bulduklarında ise eski işlerindeki ücret ve sosyal hakların altında şartlara, çoğu zaman da asgari ücrete mahkûm oluyorlar.Asgari ücret bu ülkede açlık ücreti demek. Yılın ilk 5 ayında açlık sınırı 25.092 lira, yoksulluk sınırı 81.734 liraya yükseldi. Bekar bir işçinin yaşam maliyeti ise 32.463 lira. Bunlar Mayıs ayı rakamları. Mevcut enflasyonla yıl sonuna kadar açlık sınırı 30 bin lirayı, yoksulluk sınırı 100 bin lirayı aşacak, bekar bir işçinin yaşam maliyeti de 40 bin lirayı bulacak. İşte böyle bir ortamda işçi sınıfımız asgari ücret adı altında 22.104 liralık açlık ücretine mahkûm edilmiş durumda. Hâliyle ve haklı olarak işçiler, Temmuz'da asgari ücrete zam bekliyor. İktidarın tutumu belli! İngiliz Mehmet “kemer sıkmaya devam” diyor. Çalışma Bakanı Vedat Işıkhan “daha erken” diye top çeviriyor. Sürpriz yok. Ama düzen muhalefetine de dikkat! Özgür Özel mitinglerde asgari ücrete zam nutukları atarken sermayeyi ürkütmemek için CHP'nin sözde emek komisyonu başkanı Gamze Taşcıer devreye giriyor: “Yükü sadece işverene bırakırsanız bu ekonomik ortamda işverenin bunu kaldırabilmesi mümkün değil!” Vermeyecekler! Almak için örgütlü mücadeleye! Unutma, sadece sendikalı olursan iş güvencesini savunabilirsin ve açlık ücretini reddedebilirsin! Devletten vermesini beklemeyeceğiz, örgütlü mücadeleyle patronlardan teker teker, söke söke alacağız! Devlete de gücün işçide olduğunu ancak böyle gösterebiliriz. Bardak doldu taştı! Emekçi halk isyanlarda ama bize işçi iktidarı gerek! Ancak işimiz için patronların karşısına birlik olup çıkarsak, ancak her lokmamız için birlikte savaşarak işçi iktidarının yolunu açabiliriz. İşçi düşmanı Orta Vadeli Programı çöpe atmak, İngiliz Mehmet'e “go home” demek için işçiler siyasete! Memlekete iş, aş, hürriyet getirmek için öncü işçiler göreve, Devrimci İşçi Partisi'ne, örgütlü mücadeleye!

In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what's changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.   Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC's Kenan-Flagler Business School. Editing and post-production work for this episode was provided by The Podcast Consultant.

Dev Mittar, Ph.D., Scientific Director of the ASM Health Scientific Unit discusses the use of metagenomic next generation sequencing to develop agnostic diagnostic technology, giving scientists and clinicians alike, a tool to diagnose any infectious disease with one single test. He also discusses how the ASM Health Unit is empowering scientists and leveraging microbial science innovations to address critical global health challenges and improve lives worldwide. Ashley's Biggest Takeaways The Division of Research, Innovation and Ventures is a small entrepreneurial arm of BARDA that takes on early-stage projects with high potential of turning into medical countermeasures. Prior to his role as Scientific Director for ASM Health, Mittar worked as a health scientist and program officer at DRIVe, where he focused on advancing high-impact science. He is particularly passionate about his work to develop agnostic diagnostics—a single test that uses metagenomic next generation sequencing to identify any pathogen from 1 clinical sample. Mittar discusses applications for this technology in surveillance (pandemic preparedness), variant detection, AMR and clinical settings (diagnosing complicated infections where etiology is not clearly defined). He also shares how a recent bout with illness emphasized the value and potential of this technology to save money, time, pain and suffering of the patient. Agnostic diagnostics can also help prevent the overuse/misuse of antibiotics, which are key factors in the spread of antimicrobial resistance. Furthermore, when this technology is coupled with the use of metatranscriptomics, it can provide information about the patient's immune profile that can be helpful in developing personalized treatment strategies, as opposed to a one-size-fits-all approach. ASM is organizing around 3 scientific units, ASM Health, ASM Mechanism Discovery and ASM Applied and Environmental Microbiology. These units will empower researchers and scientists to use science make a difference in the world and provide a forum for them to come together to shape the future of the field. Links for This Episode Learn More About ASM's Scientific Units. Join the Conversation on ASM Connect, our online community platform. Browse Volunteer Opportunities. Become an ASM Member. Register for ASM Microbe 2025.

Bardağın boş tarafını görmek isterseniz görürsünüz. Kusur ararsanız bulursunuz. Yanlışlık ararsanız bulursunuz. Olumsuzluk arayan gözlere sahipseniz anında bulursunuz. Zira hiçbir şey tam değildir. Hiç kimse eksiksiz ve kusursuz değildir.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Nici UE, nici Rusia nu ne vor binele, stai relax. Că ei le au pe ale lor. Și nu e că se trezesc dimineața și își zic ”ia să vedem ce putem face noi astăzi să îi fie bine României...”. Binele României venit de la cei doi coloși, UE și Rusia, este maximum o consecință a faptului că fiecare dintre ei își urmăresc propriul bine. Maximum, am zis! Că asta-i miza: a cui consecință vrem să fim, a UE sau a Rusiei? Istoric vorbind, Rusia a fost pentru noi o catastrofă continuă. Bine, pentru cei care vor să cunoască istoria. De fiecare dată când Rusia s-a gândit la binele ei și România a devenit consecința acestei gândiri, pentru noi a fost devastator. Și la fel o să fie și dacă... Istoric vorbind, integrarea europeană a România a fost o șansă continuă. Bine, pentru care vor să cunoască istoria. De fiecare dată când România s-a conectat la Europa, pe cale de consecință țara noastră a crescut și s-a modernizat. Și la fel o să fie și dacă... Prefer oricând ca România să fie o consecință a binelui pe care și-l vrea UE. Că firimiturile care ne rămân după ce se satură țările mari europene sunt ca o masă copioasă pe lângă ce ne pot oferi rușii. Care, de fapt, nu doar că nu îți oferă nimic, dar îți iau și masa cu tot cu firimiturile alea. Așa, de sanchi, doar că pot. Ah, să mai zic de atitudinea unora de o naivitate adorabilă: să creadă că România își poate fi suficientă sieși. Că poate să își asigure necesarul din producție proprie. Ar fi de râs dacă nu ar fi de plâns. Nu există NICIO țară din lumea asta care să fie în stare de așa ceva. Nu există NICIO șansă ca România să ajungă vreodată să își producă singură ce are nevoie. Nu există NICIO șansă ca ruperea de ecosistemul european să facă România să trăiască mai bine. Iar între a face parte din ecosistemul european și a face parte din ecosistemul rusesc nu cred că e dificil de ales. Cartea națională pe care credem că o jucăm nu mai este națională de multă vreme. Este internațională. Depinde de noi înspre ce direcție internațională ne îndreptăm. Iar eu tare aș vrea să fie direcția aia bună, europeană. Că e mult mai bună, așa rea cum este, decât direcția aia oribilă, rusească, știi cum zic. Ura cu care îți spun unii că ți-ar sparge capul. Asta este uluitoare. Asta este întristătoare. Asta este miza, cred. ”Lasă că vine ea vremea când vă dăm cu barda-n cap!”. ”Fugi, măh șobolanule, cât mai poți!”. ”Pământ pe tine, măh!”. De astea. Din registrul ăsta. Din partea unor oameni care, dacă ai ieși la bere cu ei, am mari dubii că ar vorbi așa. Doar că, vezi tu, pe interneți ei pot să își arunce zoaiele sufletești. Zoaiele astea sunt de înțeles. Dar doar atunci când vine vorba despre clasa politică. În totalitatea ei. Că tot ce am avut până acum au fost niște porcării sinistre. Adică, serios, în timp ce scriu rândurile astea și mă gândesc la politicienii care ne-au condus, îmi crește tensiunea și scrâșnesc din dinți. Înțeleg ura oamenilor împotriva politicienilor. Dar ce mă întristează și mă sperie un pic este că ura asta care a început împotriva politicienilor acum se revarsă și asupra celor care îi susțin pe cei din tabăra adversă. De fapt, nu este adversă, în mintea lor. Ci dușmană. Ar ajunge să îți dea cu barda în cap la propriu doar că susții pe altcineva decât le place lor? Mă îndoiesc. Sunt puțini cei care ar ajunge la violențe de astea când ajung să se uite în ochii celuilalt. Dar sunt. Din păcate. Barda asta a lor motivată de ura fermentată în zoaiele lor sufletești vine la pachet cu o orbire. Care orbire face ce face orice orbire de când lumea: îi împiedică să vadă că după ce dau cu barda tot ce mai rămâne este starea de luptă. Și că victimele sunt de toate părțile. Du-te la vot. Pentru că, odată ce barda lovește și începe lupta, și tu o să te numeri printre victime. Pentru că orbirea nu alege. Este nediscriminatorie. Îi lovește pe toți la fel. Și nu ține cont de faptul că nu ai știu ce să alegi că, îți zici, nu aveai din ce alege. Alege ne-barda, uite. Poate fi un motiv bun să te duci la vot. Să alegi ne-lupta. Să alegi ne-victimele colaterale. Din care victime colatarele cei care nu se duc la vot ajung întotdeauna să facă parte. De când lumea. Aia zic.  

Feathers & Foes are back!  Let us know what you thought abbout issue 20 at feathersandfoes@gmail.com www.thehuntresspodcast.com www.patreon.com/wrightonnetwork BlueSky: Huestone44.bsky.social & mtnflwr1.bsky.social Birds of Prey: Issue 20       Released: April 2, 2025  Writer: Kelly Thompson      Art: Sami Basri with Vicente Cifuentes    Colors: Adriano Lucas   Lettering: Clayton Cowles    Editor: Jessica Berbey     Group Editor: Rob Levin Title: On the Run Part 1 In Gotham, Batgirl Cassandra Cain is investigating an apartment crime scene littered with clues. She bumps into Batman who agrees the crime scene belongs to the Birds of Prey. Back at the Birds' Headquarters, Oracle attempts to go through all the evidence. The group knows this is all a trap of some sort but there needs to be several in person investigations to solve what has happened and how it relates to a stolen experimental drug. They split up. That night in Gotham, Sin and Batgirl are on a stakeout. Sin is excited and apologizes for being a lot to put up with. Batgirl reassures her. They are a lot alike, trained to be weapons, bad people always want them. However they both are different inside and it's good. Sin gives her a hug. Meanwhile, Barda drops off Dinah in Tokyo. She makes her way down from the roof into a large theater where a demonstration of a new invisibility suit is underway. Dinah is shocked at how effective it is, Oracle calls it an industry game changer. Barda has boom tubed into United Arab Emirates and a small town that appears deserted. She investigates a strange nearby skyscraper. Although it has power, it too is empty. After getting into the penthouse she hears someone from the air ducts call out to her.  Back in Gotham, Sin and Bargirl are curious when their target leaves a club only to descend into the sewers. They carefully follow.  Barda reaches up to the grate of the air duct when tendrils of black slice down upon her. She drops her Megarod. The inky creature quickly heads for it. The room tilts as an alarm sounds. Barda's Megarod falls out the window with the ink creature. It grabs it and turns into a woman with glider wings. Barda is too busy to notice as the entire penthouse is launched into space. Oracle is trying to get feedback from Black Canary as Barda's intermittent communicator signal comes through. Oracle tells Barda all the Birds are under attack. Barda says she's in space, right before she discovers a bomb's onboard. It goes off with a huge boom and the ship explodes. Oracle frantically announces: “All Teams. This is a code black. Barda is down. I repeat, code black. Barda is down”.   Elsewhere a shadowy figures looks at pictures of the Birds saying “one down, four to go.”  

durée : 00:00:57 - Le musicien folk toulousain "Le Barda" - Country, folk, blues, Le Barda est un touche-à-tout de génie ! Découvrez aujourd'hui sur La Scène Toulousaine un grand musicien...

Feathers and Foes are back to talk about the Kelly Thompson banger! Write to us at feathersandfoes@gmail.com or www.patreon.com/wrightonnetwork Bluesky: huestone44.bsky.social Birds of Prey: Issue 19        Released: March 5, 2025  Writer: Kelly Thompson      Art: Juann Cabal      Colors: Adriano Lucas   Lettering: Clayton Cowles    Editor: Jessica Berbey     Group Editor: Rob Levin Title: Divide and Conquer Part 2 At the Lake House, Dinah and Sin's trap has succeeded and their stalkers attack. A huge fight ensues with Oracle supplying help via drones. But when Dinah moves in front of the window, she's hit by a sniper's bullet. Meanwhile in the magical streets of The Seam, Big Barda continues her battle with the golems. She smashes them only for them to reform. No problem. She opens a boom tube to the moon and hits or tosses them through. She grabs their controller, Barter, and threatens to do the same to him unless he tells her how many others are after Batgirl and Constantine. Elsewhere in The Seam, the demon controlled Constantine continues it's attempt to get Batgirl to free it from it's bonds. Needless to say she's not even tempted. When the final golems attack, Batgirl smashes them then separates the parts by tossing them in various stores and barrels along the road.  Back at the Lake House, Sin loses it when Dinah is shot at goes full Megaera, with green light blasting out of her and tendrils all doing their thing. She, or is it they, float out of the roof and threaten the League of Shadows, or whatever splinter cell this is, that they better gather their fallen and leave or she will take them apart. She further threatens to end them if she ever sees them again. Afterward Sin returns to care for Dinah. Dinah is worried if the being who just threatened the attackers was Sin or all Megaera. Sin isn't sure and Dinah reassures her they will find someone who can help. Back in The Seam, Batgirl and the demon infested Constantine reach the portal where the demon must be deposited. She rebuffs it again and is about to toss it in when Barda arrives to kick it through. A few moments later, the freed Constantine returns to the street. Dinah and Sin settle down to watch the sun rise at the Lake House. Sin expresses another concern. Some of the League of Shadows assassins she threatened appeared to be happy. She's possibly given them something new to covet: Megaera.   

Amerikalıların günde 330 milyona kadar plastik pipet kullandığı tahmin ediliyor - şimdi Başkan Trump bunları aşamalı olarak kaldırma çabalarını tersine çevirdi. Peki çevresel etkiler neler ve Avustralya plastik pipetleri yasaklama konusunda hangi aşamada?

Send us a textProf. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx ( https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.html ), a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need. Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx. As physician, Prof. Dr. Riedemann was appointed Vice Director (“Leitender Oberarzt”) of Intensive Care Medicine, and led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg, Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. Prof. Dr. Riedemann's research has been awarded with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.#NielsRiedemann #InflaRx #Inflammation #ComplementComponent5a  #Sepsis #AcuteRespiratoryDistressSyndrome #Covid #ARDS #GOHIBIC #Vilobelimab #PyodermaGangrenosum #ChronicSpontaneousUrticaria #HidradenitisSuppurativa #Preparedness #BARDA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Sürekli başkalarına yetişmeye çalışırken kendini ihmal ettiğini fark ettin mi? Peki, sen tükenmişken başkalarına nasıl destek olabilirsin? Bu bölümde, kendimizi ihmal etmeden dengeli ve tatmin edici bir hayat yaşamanın yollarını konuşuyoruz.

David Druid och Linnea Wikblad är marginalfria, Cassandra Klatzkow fryser sina ägg och Cecilia Uddén om vapenvilans första dag. Lyssna på alla avsnitt i Sveriges Radio Play. Hela veckans Morgonpasset i P3 hör du i Sveriges Radio Play.Vi kan inte få nog av Jean-Pierre Barda som lär oss allt om Village People! Cassandra Klatzkow från podden ”Det skaver” fryser sina ägg och berättar om processen! Mellanösternkorren Cecilia Uddén på plats i Jerusalem om vapenvilans första dag. David Druid och Linnea Wikblad tillhör minoritetsgruppen ”marginalfria”. Linnea förstör avokadon för miljöns skull – clean ween! Matilda Rånge på P3 Nyheter om vapenvilan och att Trump svärs in. Matilda Rånges obekväma falska lilla hål: Router.Tidpunkter i avsnittet:18:06 Nyhetsfördjupning: Vapenvilan i Gaza.23:29 Jean-Pierre Barda om Village People och YMCA.46:37 Nyhetsfördjupning: Trump svärs in.57:33 Matilda Rånges obekväma falska lilla hål: Router.1:02:52 Cecilia Uddén i Jerusalem.1:18:09 Cassandra Klatzkow.Kapitellänkarna ovan leder till avsnittet utan musik i Sveriges Radio Play.Programledare: David Druid och Linnea Wikblad.

Antonín Kotík vykládal příjmení Velda z adjektiva velký. Patřilo by tak mezi pojmenování podle vlastností. Podle Josefa Beneše je však třeba vykládat příjmení Velda spíše z rodného jména s příponou -da, analogicky k příjmením jako Karda z Karel, Šalda z Šalamoun, Barda z Bartoloměj apod. Základem příjmení Velda bylo nejspíše rodné jméno Veleslav, Velimír apod. V současnosti u nás nosí příjmení Velda/Veldová 25 obyvatel.Všechny díly podcastu O původu příjmení můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

This week Dr. Evan Loh, Paratek CEO, returns to Off theShelf to share the latest in the biopharmaceutical company's partnership withthe Biomedical Advanced Research and Development Authority's (BARDA's) Project BioShield. Paratek's antibiotic, NUZYRA (omadacycline) has beendesignated “an essential” medicine by the FDA, and Loh provides an updateon the progress made in onshoring of manufacturing of NUZYRA, from theproduction of API through finished drug product for both IV and oralformulations. Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek's public-private partnership with BARDA played in developing manufacturing capability.Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations incombatting these and other healthcare threats. Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protectthe warfighter.     Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week Dr. Evan Loh, Paratek CEO, returns to Off the Shelf to share the latest in the biopharmaceutical company's partnership with the Biomedical Advanced Research and Development Authority's (BARDA's)  Project BioShield.  Paratek's antibiotic, NUZYRA (omadacycline) has been designated “an essential” medicine by the FDA, and Loh provides an update on the progress made in onshoring of manufacturing of NUZYRA, from the production of API through finished drug product for both IV and oral formulations.  Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek's public-private partnership with BARDA played in developing manufacturing capability. Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations in combatting these and other healthcare threats.  Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protect the warfighter.     Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Prakash Narayan is a distinguished biotech executive with over 20 years of experience in leading IND- and BLA-enabling programs from concept through clinical trials for heart, lung, kidney, and liver indications. As a founding member of a startup biotech that became a publicly traded company, Dr. Narayan has demonstrated exceptional leadership skills and a proven track record in nonclinical and translational R&D, attracting approximately $30 million in non-dilutive funding as a Principal Investigator from various organizations including NIH, NSF, DoD, and BARDA 00:00 Introduction to the Life Science Success Podcast 00:37 Sponsor Message: D3 Digital Media Marketing 01:10 Guest Introduction: Dr. Prakash Narayan 01:51 Journey from Academia to Biotech Executive 04:34 Growing a Startup into a Publicly Traded Company 06:49 Drug Development Process: From Discovery to FDA Filings 12:53 Challenges and Future of Cell-Based Therapies 16:10 Predictive Analytics in Biomedical Science 19:10 Adapting Approaches Across Disease Areas 22:56 Precision Medicine in Clinical Trials 24:40 Understanding Fatty Liver Disease 25:00 Precision Medicine: A Tailored Approach 25:25 Repurposing Drugs for Kidney Disease 27:10 The Role of Biobanks and Electronic Health Records 28:26 Non-Dilutive Funding: Pros and Cons 32:56 Exploring Transcriptomics and Functionomics 36:55 The Impact of Technology and AI in Medicine 40:53 Inspiration and Concerns for the Future 47:42 Final Thoughts and Advice for Entrepreneurs  

Join us on Friday Nights @ 7:00 PM EST on our Youtube channel  https://www.youtube.com/@WeirdScienceComics when we do the Absolute show LIVE!   YouTube: https://www.youtube.com/@WeirdScienceComics This Week's Patreon-Exclusive Spotlight Show is Two-Face #1 & Poison Ivy #28   Listen to the Spotlight Podcast by signing up to our Patreon - https://www.patreon.com/weirdscience   0:00:00 - Intro 0:17:18 - Action Comics #1078 0:49:59 - Batman #155  1:21:27 - JSA #2 1:43:17 - Shazam! #18 2:03:24 - Batgirl #2 2:13:06 - Birds of Prey #16   FOLLOW WEIRD SCIENCE COMICS Twitter:  https://twitter.com/WeirdScienceDC  Patreon: https://www.patreon.com/weirdscience DC Comics Review Site: https://bit.ly/WeirdScienceDC Marvel Review Site: https://bit.ly/WeirdScienceMarvel   SUBSCRIBE TO WEIRD SCIENCE COMIC PODCASTS:  DC Comics Podcast iTunes - https://apple.co/47jNeme Spotify - https://spoti.fi/2XzDALI Stitcher - https://bit.ly/45XPtKS  

Birds of Prey: Issue 16 Released: December 4, 2024 Writer: Kelly Thompson Art: Sami Basri Inker: Vicente Cifuentes Colors: Adriano Lucas Lettering: Clayton Cowles Editor: Jessica Berbey Group Editor: Rob Levin Title: Bird Undercover Part 3 Cassandra Cain's undercover mission into The Ninth Day Corporation has landed her in a secret sub-basement labyrinth facing Bella, a mutated woman who is now a dog like werewolf creature. However, after Cass uses a brick to break Bella's electronic collar, the beast becomes a friend. Cass uses Bella to trick her way into the guard's chamber. She takes some of the guard's equipment before climbing up the elevator cable and back into the ventilation ducts. She sees a woman about to be injected with a green substance and crashes into the room. She frees the woman who flees into the air duct. Cass now finds herself facing Xane, Jens, and Chet again. She sees that Xane is still wearing her secret communication bracelet. She uses a smoke grenade to distract him as she presses something to activate the bracelet. Except this has given one of the others time to hit her in the back with the syringe. Meanwhile at the Birds Headquarters, the other Birds have been anxiously awaiting word from Cass since she missed the last two check in times. Oracle is finally able to translate the message Cass send before her initial capture and the group sets out through one of Barda's boom tubes into the basement lab of the Ninth Day Corporation. As the scientists flee, gas is released and the Birds done their gas masks. They're then confronted by 4 grotesquely muscled mutated women. Black Canary, Big Barda, Onyx, and Grace take them out. However, as Black Canary uses a device to allow Oracle access into the computer she sees a sight that horrifies them: a grotesquely muscled mutated Cassandra Cain.    Write to us at feathersandfoes@gmail.com www.thehuntresspodcast.com Bluesky: @huestone44.bsky.social www.patreon.com/wrightonnetwork  

(00:00:00) The Geek Matrix Pod reviews DC's Weekly Comics Releases This week, (11/20/24), that's: (00:52:42) #Shazam 18 (01.02.07) #JSA 2 (01.12.35) #PoisonIvy 28 (01.23.50) #BirdsofPrey 16 (01.31.40) #TwoFace 1 (01:45:30) #ActionComics 1078 (01.54.50 ) #Batman 155 (02.15.25) #AbsoluteSuperman 2 (00:47:58) Plus our Honorable Mentions covered each week by Josh! Here's the run down – Variants Fico Ossio's variant for JSA #2 is like beautiful. David Nakayama's cover D for Action Comics 1078 is literally beautiful. Mateus Manhanini on Absolute Superman 2 is on fire and both JonBoy Meyers and Bjorn Barends draw covers I'd love to have. Titles DC's Batman Smells, Robin Laid an Egg #1 - John Stewart, The Secret Six, John Constantine, The Joker, Deadman, Dr. Mid-Nite, Vixen, and Superman get their own little crazy Holiday stories from DC's annual anthology book. And it's not bad. Typical seasonal anthology, if you can get past the cover. 7/10 DC Horror Presents: Creature Commandos #3 – This is dark, gritty, written well and a fun read. I hope that it continues because so far, we've got a really good main universe Horror book here, and I'd like to keep it that way. 8.25/10 Batman / Santa Claus: Silent Knight Returns #2 – It's amazing art, stellar, which a big cast of popular characters and a story that, so far, looks to out do our last go round with the Silent Knight. I'm all in for this series. Good time. 8/10 DC Horror Presents... #2 – Two twisted tales for The Penguin and Scarface. The Penguin one wasn't bad., The Scarface one was really good, if not a little messed up. Good stuff. 7.75/10 Little Batman Month One #2 – This continues to be a fun story for everyone, and suitable for the younger crowds. The comedy is just great. 8/10 Batgirl #2 – Continuing the story, Cass is forced to do things she doesn't want… like leave Gotham. But with this new enemy, is that the right choice? Second issue, and it's a killer. 8.25/10 Scooby-Doo, Where are you 131, Batman and Scooby Doo Mysteries #12 – Dash comes back next week. #Shazam #JSA #PoisonIvy #BirdsofPrey #TwoFace #ActionComics #Batman #AbsoluteSuperman #DCAllIn #AllIn #Absolute #DCComics #comics #comicbooks --- Support this podcast: https://podcasters.spotify.com/pod/show/thegeekmatrixcomics/support

Welcome, Bat-fans, to another fang-tastic episode of The BATTASS Podcast! Today, your hosts, Clay McCormack and Sean Murphy, are slithering into the world of Batman Beyond to cover two unforgettable episodes: *The Call* and *Curse of the Kobra*. But before we dive in, I need to get something off my chest—or maybe off my arm, because that's where yet another snake just sank its teeth into me! You'd think after years of handling snakes, I'd have figured out how to avoid getting bitten, but nope! It's like these slippery little suckers are out to get me. But hey, they say venom builds character, right?Anyway, back to Gotham! First up, *The Call* is an epic two-parter that introduces Terry McGinnis to the Justice League of the future. It's a jaw-dropping crossover featuring Superman, Barda, and more, with Terry stepping into the big leagues. Clay and Sean will dig deep into the intrigue, betrayal, and the weighty legacy of heroes old and new. And believe me, there's more venom in this story than even my snake pit at feeding time!Next, we've got *Curse of the Kobra*, where Terry faces off against a deadly martial arts cult led by the menacing Kobra. There's action, suspense, and plenty of reptilian vibes—though thankfully, no actual snake bites (unlike my day). Clay and Sean will unpack this pulse-pounding tale and the evolution of Terry as Batman as he goes toe-to-toe with some of his most formidable foes yet.So, while I'm busy nursing another bite wound and wondering if snake wrangling was really the right career choice, Clay and Sean are here to deliver sharp insights, compelling analysis, and, as always, a healthy dose of Bat-love. Grab your headphones and join The BATTASS Podcast for another hiss-terical and action-packed episode!

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS' national and international footprint, and the significant partnerships with organizations like Children's National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

Tune in for the latest news and trends in this month's episode of the Scope of Things, where host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves' disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA's new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more. Joining the discussion is Aaron Mackey, vice president of AI and data science at Lokavant, who talks about the unintended consequences of decisions made during trial planning that can lead to questionable conclusions, how AI and ML are helping with the diversity issue in trial participation, and his stop gap emergency plan to keep trials on track if there is no digital support available. SHOW NOTES News Roundup Phase 3 trial for Graves' disease Article in Clinical Research News  Quality of life measures in cancer studies Study in Journal of Clinical Oncology Article in Clinical Research News Rapid recruitment for a diagnostic tampon trial Article in Clinical Research News Reference trial emulation Study in PLOS Medicine  Walgreens/BARDA partnership News brief in Clinical Research News “Detective” algorithm for improving trial design Study in Nature Genetics Exclusion of people with Duffy-null phenotype Study in JAMA Network Open    The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

En Oaxaca continúa la suspensión de clases en cinco regiones del estado El Poli te invita a participar en el concurso SexOlimpiadas PolitécnicasSanciona EU a dos empresas con sede en México propiedad de traficantes de fentanilo  Más detalles en nuestro Podcast

Is the world readying for Ezekiel 38-39?  Do NATO, the EU, and Russia all know that nuclear war is coming?  Why doesn't America know/isn't being warned?  Why are post vaxx statistics not being published in some Scandinavian countries any longer?  The WEF now admits that the Covid assault on society was all about testing our ____.  What does candidate Trump mean when he says, "If you elect me, Christians, you won't have to vote any more?"  Trump's assassins were previously both actors in a _____.  Israel is joining what war?  Please join Steve and Bonnie for a look into what could be our final weeks before ... our walking a path that will lead to ...  Yeshua ...  face-to-face. Plandemics There never was a Corona virus: https://www.globalresearch.ca/there-never-was-a-virus-there-never-was-a-pandemic/5841105 Post-vaxx death and illness stats so bad Norway won't publish: https://substack.com/@stevekirsch/p-148189713 A mountain of sites reporting vaxx injury/death: https://rootforamerica.com/covid-vaccine-dangerous-and-deadly/ Virologist - mpox in Covid vaxx: https://halturnerradioshow.com/index.php/news-selections/world-news/virologists-blow-the-whistle-mpox-is-actually-known-side-effect-of-covid-vax FDA concealed study of Mpox vaxx on 100,000 military personnel, concluded “safe and effective” because of trials of 24 monkeys instead: https://open.substack.com/pub/karenkingston/p/the-fda-authorized-and-then-concealed?r=12g59e&utm_campaign=post&utm_medium=email People are too smart for any more vaxxes so let's release genetically modified mosquitoes: https://open.substack.com/pub/2ndsmartestguyintheworld/p/psyop-eee-massachusetts-town-approves?r=12g59e&utm_medium=ios MUST DOWNLOAD!!! Pfizer doc 5.3.6, postmarketing experience, 1291 specific adverse reactions, intended to be unavailable for 75 years: https://childrenshealthdefense.org/wp-content/uploads/pfizer-doc-5.3.6-postmarketing-experience.pdf#page=30 List of studies showing C19 vaxx “worst healthcare disaster in world history”: https://rootforamerica.com/covid-vaccine-dangerous-and-deadly/ WEF admits – C19 a beta test to measure blind compliance: https://leohohmann.substack.com/p/world-economic-forum-finally-tells?r=qrouj&utm_medium=ios&triedRedirect=true Natural News – Covid was a beta test: https://www.naturalnews.com/2024-09-12-wef-admits-covid-test-obedience-globalism.html Nanobots capture living cells to build something new: https://t.me/GodsRoadmap/2148 Walgreen's new wealth – vaccine “research” on women/children with $100 mil contract from BARDA: https://open.substack.com/pub/sashalatypova/p/walgreens-pharmacy-chain-gets-100m?r=12g59e&utm_campaign=post&utm_medium=email Outpouring of Spirit needed because medical system as overwhelmingly failed us:  https://open.substack.com/pub/vigilantfox/p/horrific-vaccine-injury-leaves-23?r=12g59e&utm_campaign=post&utm_medium=email Experiments on children easier after new rule of Jan. '24: https://open.substack.com/pub/sashalatypova/p/the-fda-simplifies-experimentation?r=12g59e&utm_campaign=post&utm_medium=email Experts baffled at death rates in the young: https://fackel.substack.com/p/ive-never-seen-anything-like-this?utm_source=substack&utm_campaign=post_embed&utm_medium=web US navy crippled by adverse reactions of Covid vaxx: https://www.naturalnews.com/2024-08-28-navy-crippled-covid-vaccines-17-ships-sidelined.html Covid vaxx effect on economy: https://www.thetimes.com/uk/politics/article/sickness-benefits-mental-health-ct328xxjc Physician who quit at beginning of Covid looks back: https://thepeoplesvoice.tv/top-doctor-we-were-told-to-deliberately-kill-millions-of-covid-patients-using-ventilators/ NWO Plans Albert Pike's 3 World Wars: https://expose-news.com/2023/10/21/albert-pikes-plan-for-three-world-wars/ Albert Pike's 3rd WW in the making: https://medium.com/@newsonchain/albert-pike-three-world-wars-a-one-world-government-c7fefff7008a

Violencia en Sinaloa impide rescate de una tigresa No te pierdas el recorrido guiado por la  Sierra de Santa CatarinaServicio secreto de EU asume responsabilidad por el atentado contra Trump 

OPPOSITES ATTRACT NGA BA?Sino kaya kina Barbie Forteza at David Licauco ang “very demure, very cutesy and very mindful?” Totoo bang maraming nambabash kay Barbie na gumaganap bilang Adelina sa Kapuso family drama na “Pulang Araw” dahil hindi raw ito magaling umarte? Ano kaya ang say dito ni David aka Hiroshi? Forda BarDa fans out there — malalaman n'yo na lahat ‘yan sa bagong episode ng Updated with Nelson Canlas! Hosted on Acast. See acast.com/privacy for more information.

Bu bölümde yaşların hediyelerinden, yaşlanma kelimesini olgunlaşma ile değiştirmekten bahsediyoruz. Bardağın ne tarafından bakarsak artık... Keyifli dinlemeler

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biopharma news on August 21, 2024 saw changes in Biomarin's C-suite, with Greg Friberg and James Sabry taking over R&D and business development. BridgeBio launched GondolaBio for rare disease drug programs, while Regeneron faced FDA setbacks for a myeloma drug. Avidity and Kymera raised funds, Walgreens partnered with Barda, and Merck licensed an antibody drug conjugate. Thermo Fisher Scientific supported oncology research with new developments in clinical trials. Overall, the industry saw leadership changes, setbacks in drug approvals, fundraising activities, partnerships, and innovations in clinical trials.A study suggested that patients on Novo Nordisk's semaglutide may have a higher risk of suicidal thoughts. The FDA denied Regeneron's drug approval for myeloma due to manufacturing issues. Lawmakers raised concerns about US biopharma companies working with the Chinese military. Novo Nordisk, Eli Lilly, and Sanofi are each focusing on different markets for their diabetes GLP-1 drugs. The impact of recent Supreme Court decisions on the healthcare and pharma industries is discussed, including challenges against regulations and reforms proposed by President Joe Biden. The uncertainty could jeopardize FDA authority and provisions in the Inflation Reduction Act, adding complexity for pharma companies.The Biosecure Act revealed gaps in domestic drug manufacturing readiness in the US. Different strategies of Novo Nordisk, Eli Lilly, and Sanofi in developing and distributing their GLP-1 drugs were highlighted. A gene therapy patent ruling raised intellectual property concerns, Genentech closed its cancer immunology group, and layoffs were reported in the industry. House lawmakers expressed worries about US biopharma companies collaborating with the Chinese military on trials. Aadi Bioscience plans to lay off 80% of its R&D staff.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.J&J has acquired heart failure implant maker V-Wave for up to $1.7 billion, while Medtronic reiterates its unchanged diabetes strategy despite a partnership with Abbott. Histosonics secured $102 million for a noninvasive tumor treatment using sound waves, and Edwards acquired Genesis' TAVR technology. The FDA approved NowDiagnostics' at-home syphilis test, offering results in 15 minutes with a drop of blood. The biotech industry remains strong in 2024, with startups thriving and technology advancements. Small biopharma and CROs are adopting multiple trial technologies, as per a recent survey.23andMe, known for consumer genetic testing, focuses on therapeutics development despite financial struggles and data breach lawsuits. Their lead candidate targets a new cancer treatment pathway using checkpoint inhibitors. Lilly's diabetes drug tirzepatide shows promise in reducing type 2 diabetes risk, while J&J's Rybrevant and Lazcluze combo is FDA-approved for lung cancer. Avidity and Kymera raised funds, Walgreens partnered with BARDA, and Merck licensed an antibody drug conjugate. Humana settles Medicare Part D fraud allegations, Steward hospitals in Massachusetts must sell five facilities, and McLaren Health Care faces another ransomware attack.Eli Lilly's tirzepatide demonstrates a 94% risk reduction for type 2 diabetes in overweight adults, and J&J's Rybrevant combo is the first chemo-free treatment for non-small cell lung cancer. Walgreens and BARDA collaborate to boost decentralized clinical trials, while three drugs are projected to drive drug price negotiation savings in 2026. Quality Assurance and Regulatory Affairs roles are crucial for market access, AbbVie and Genmab expand Tepkinly's European label, and biopharma companies like Lykos, Galera, and Grail announce staff reductions. AstraZeneca receives FDA approval for Imfinzi's perioperative use.Lykos restructures with significant staff cuts post-FDA rejection of their therapy, Acelyrin shifts focus to thyroid eye disease treatment after layoffs. Biotech IPO sizes are increasing despite slow IPO rates, Lilly opens an R&D hub in Boston, Ovid and Lexicon downsize staff. Stay informed with Biopharma Dive's comprehensive coverage of biotech and pharma industry news.

"The intersection of medicine, business and courageous creativity is where I've spent most of my career" Wendy Dean MD     In S5 E9 I am delighted to introduce another "heavy hitter" in healthcare thought leadership and transformational practice, Wendy Dean MD, president and co-founder of Moral Injury of Healthcare. Dr Dean is an alum of Smith College and the University of Massachusetts Medical School. She trained in surgery and psychiatry at Dartmouth Hitchcock Medical Center. After practicing for a decade, Wendy worked for the US Army, where she managed regenerative medicine research funding and guided strategy for a $70M investment in the emerging field of hand and face transplants. In that position, and as a senior executive at a large nonprofit in Washington, D.C., she worked closely with both the civilian and military medical communities, and many government agencies--BARDA, NIH, WHOSTP, NASA, DARPA--to develop novel strategies to restore form, function and appearance to ill and injured service members. She remains part of those communities as a board member and prize judge.          In describing her mission she says,"My focus now is on finding innovative ways to make medicine better for both patients and physicians through my own non-profit and by helping new talent and new ventures realize their big ideas."               Farming, fencing, photography, and riding big, opinionated horses keeps me focused outside of work.               In this conversation Wendy discusses the concept and definition of moral injury in medicine, how it is distinct but can co-exist with burnout, the implication of this for medical systems and organisations and the evolution of her own thinking and practice in this area since the publication of the OpEd she co-authored in 2018 "Clinicians aren't burning out they are suffering from moral injury". We discuss her book "If I Betray these Words" from idea to fruition and the challenges and opportunities of elevating clinical voices through story. The major part of this conversation is directed towards transformational leadership and practice in the modern day "business" of healthcare. Who is doing it well and what is working well? Wendy's commitment to mission and purpose and willingness to challenge her own and our collective thinking and practice permeates this entire episode. Thank you for energising me and for all the work that you do to move us forward towards a brighter future for healthcare. Links/References/Reading/Listening:https://wendydeanmd.comhttps://www.linkedin.com/in/wendy-dean-md/https://www.fixmoralinjury.org/what-is-moral-injuryhttps://www.penguinrandomhouse.com/books/718606/if-i-betray-these-words-by-wendy-dean-and-simon-talbot/ https://www.statnews.com/2018/07/26/physicians-not-burning-out-they-are-suffering-moral-injury/https://podcasts.apple.com/au/podcast/43cc/id1715895952 The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

El Camino de los Faros o “Camiño dos Faros” es la ruta más moderna y no oficial de los diferentes Caminos de Santiago. Quizá por eso sea tan desconocida, pero es un camino que bordea la Costa da Morte con una longitud de 200 km pegados al mar, bordeando playas y acantilados de una belleza espectacular. Una ruta senderista que sin duda, merece la pena hacer, pero no es para principiantes. El Camino de los Faros es una de las rutas de senderismo más fascinantes de Galicia, una región del noroeste de España conocida por sus paisajes dramáticos, su rica historia y su cultura vibrante. Este sendero recorre aproximadamente 200 kilómetros a lo largo de la costa de la Costa da Morte, desde Malpica hasta Finisterre, ofreciendo una experiencia única que combina naturaleza, historia, y cultura. Origen y Filosofía del Camino de los Faros Historia El Camino de los Faros fue concebido por un grupo de amigos locales en 2012, conocidos como los “trasnos” (duendes en gallego), que deseaban crear una ruta que conectara los numerosos faros de la Costa da Morte, una región famosa por sus abruptos acantilados y su mar embravecido. Estos faros han sido testigos de numerosos naufragios y son emblemáticos de la relación de Galicia con el mar. La ruta fue creada para mostrar la belleza de la costa, promover el turismo sostenible y revalorizar el patrimonio natural y cultural de la zona. Filosofía La filosofía del Camino de los Faros se centra en la idea de disfrutar y respetar la naturaleza. La ruta no solo busca atraer a los senderistas por sus paisajes espectaculares, sino también fomentar un respeto profundo por el medio ambiente y las comunidades locales. Esto incluye la conservación de la flora y fauna, la promoción de prácticas sostenibles, y el apoyo a la economía local. Recorrido y Etapas El Camino de los Faros se divide en 8 etapas, cada una con sus propias características únicas. A continuación, se describe cada etapa en detalle: 1. Malpica - Niñóns (21 km): La ruta comienza en Malpica, un pintoresco puerto pesquero. El sendero se adentra en un paisaje costero accidentado, con vistas espectaculares del Atlántico y los acantilados de la Costa da Morte. Destacan la Playa de Seaia y la Punta Nariga, con su moderno faro. 2. Niñóns - Ponteceso (27 km): Esta etapa atraviesa playas salvajes como la Playa de Niñóns y la Playa de Barda. Se pasa por los acantilados de Roncudo, famosos por sus percebes, y se llega a Ponteceso, tierra del poeta Eduardo Pondal. 3. Ponteceso - Laxe (25 km): El camino sigue el curso del río Anllóns, hasta llegar a la desembocadura en la Ría de Corme y Laxe. La Playa de Laxe y su encantador pueblo marinero son los puntos culminantes de esta etapa. 4. Laxe - Arou (17 km): Desde Laxe, la ruta pasa por la Playa de Soesto y sube hasta el Monte Castelo de Lourido, ofreciendo vistas impresionantes de la costa. El final de la etapa se encuentra en el pequeño pueblo de Arou. 5. Arou - Camariñas (23 km): Esta etapa es conocida por sus paisajes abruptos y el Faro Vilán, uno de los más emblemáticos de Galicia. Se camina por playas solitarias y se llega a Camariñas, famosa por su encaje de bolillos. 6. Camariñas - Muxía (32 km): Esta es una de las etapas más largas y exigentes. Se pasa por el Santuario de la Virgen de la Barca en Muxía, un lugar de peregrinación con vistas espectaculares del mar. 7. Muxía - Nemiña (24 km): La ruta sigue la costa hacia el sur, pasando por la Playa de Lourido y el Faro de Touriñán, el punto más occidental de la España peninsular. La etapa termina en la tranquila playa de Nemiña. 8. Nemiña - Finisterre (26 km): La última etapa lleva a los caminantes hasta el Cabo Finisterre, conocido en la antigüedad como el “fin del mundo”. El faro de Finisterre ofrece una vista impresionante y es un lugar de reflexión y celebración para los caminantes. Aspectos Destacados y Atractivos Paisaje y Naturaleza El Camino de los Faros ofrece un acceso incomparable a la belleza natural de la Costa da Morte. Los senderistas pueden disfrutar de playas vírgenes, acantilados dramáticos, bosques de pinos y eucaliptos, y formaciones rocosas únicas. La biodiversidad es rica, con numerosas especies de aves marinas y una flora variada que incluye plantas endémicas de la región. Faros Cada faro a lo largo del camino tiene su propia historia y características únicas. El Faro de Punta Nariga, con su diseño moderno, contrasta con el Faro Vilán, que tiene una historia trágica vinculada a naufragios. Estos faros no solo sirven como puntos de referencia, sino también como símbolos de la conexión de Galicia con el mar. Cultura y Patrimonio La ruta pasa por numerosos pueblos pesqueros, cada uno con su propio carácter y tradiciones. Los caminantes pueden explorar la cultura local a través de su gastronomía, festividades, y artesanía, como el encaje de bolillos en Camariñas. Además, sitios históricos como el Santuario de la Virgen de la Barca en Muxía y la historia del Cabo Finisterre añaden una dimensión cultural profunda a la experiencia. Logística y Consejos Mejor Época para Caminar El Camino de los Faros se puede realizar en cualquier época del año, aunque la primavera y el otoño son ideales debido a las temperaturas moderadas y la menor afluencia de turistas. El verano ofrece más horas de luz, pero puede ser más concurrido y caluroso. Equipamiento Es esencial llevar ropa y calzado adecuados para senderismo, protector solar, agua y comida. También se recomienda un mapa detallado de la ruta y un teléfono móvil con suficiente batería, ya que algunas áreas pueden ser remotas. Alojamiento A lo largo del Camino de los Faros, hay una variedad de opciones de alojamiento que incluyen albergues, pensiones, y casas rurales. Es aconsejable reservar con antelación, especialmente en temporada alta. Seguridad Los senderistas deben estar preparados para cambios climáticos repentinos y condiciones costeras variables. Se recomienda caminar en grupo o informar a alguien de la ruta planeada. También es importante respetar las señales y advertencias locales. Conclusión El Camino de los Faros es una joya del senderismo en Galicia, ofreciendo una mezcla única de belleza natural, patrimonio cultural y desafío físico. A través de sus etapas, los caminantes pueden experimentar la costa salvaje de la Costa da Morte, descubrir la historia de sus faros y sumergirse en la cultura local. Es un camino que invita a la reflexión, la aventura, y el descubrimiento de uno de los paisajes más impresionantes de España. Puedes leer más y comentar en mi web, en el enlace directo: https://luisbermejo.com/fragmentos-zz-podcast-05x48/ Puedes encontrarme y comentar o enviar tu mensaje o preguntar en: WhatsApp: +34 613031122 Paypal: https://paypal.me/Bermejo Bizum: +34613031122 Web: https://luisbermejo.com Facebook: https://www.facebook.com/ZZPodcast/ X (twitters): https://x.com/LuisBermejo y https://x.com/zz_podcast Instagrams: https://www.instagram.com/luisbermejo/ y https://www.instagram.com/zz_podcast/ Canal Telegram: https://t.me/ZZ_Podcast Canal WhatsApp: https://whatsapp.com/channel/0029Va89ttE6buMPHIIure1H Grupo Signal: https://signal.group/#CjQKIHTVyCK430A0dRu_O55cdjRQzmE1qIk36tCdsHHXgYveEhCuPeJhP3PoAqEpKurq_mAc Grupo Whatsapp: https://chat.whatsapp.com/FQadHkgRn00BzSbZzhNviThttps://chat.whatsapp.com/BNHYlv0p0XX7K4YOrOLei0

The Biomedical Advanced Research and Development Authority (BARDA) helped bring Moderna's mRNA vaccine through clinical trials to market. BARDA's Division of Research, Innovation, and Ventures (DRIVe) is its in-house biotech venture capital firm, charged with identifying and incubating technologies for U.S. biodefense and preparedness.Today's interviewee is Dr. Sandeep Patel, the Director of DRIVe from March 2020 to March 2024. Patel helped architect the program's VC-inspired model and led the organization through its COVID response. We covered:(00:00) Introduction(00:20) How cost-effective is BARDA?(09:38) Venture-capitalism in government(26:14) Hiring talent(34:35) Question grab-bag This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.statecraft.pub

IMSS aplica prueba de detección de hepatitis C Encarcelan a la presidenta municipal de San Juan Cuicatlán, Oaxaca  Biden debe reconsiderar seriamente el futuro de su candidatura: Barak ObamaMás información en nuestro podcast

Please remember to rate and review our podcast! Check out your YouTube channel @comadresycomics CHISME DE LA SEMANA: Anger over the use of AI in art heated up over the weekend after Adi Granov called out DC cover artist Francesco Mattina for using AI in a variant cover for Superman #18. ON MY RADAR: House of the Dragon on HBO season 2 & DC's newest YA graphic novel, Barda. HORA DE LA CERVECITA:  Tropicália by Creature Comforts BOOK REVIEW: Doña Quixote: Rise of the Knight by Rey Terciero (Author), Monica M. Magaña (Illustrator) EN LA LIBRERIA: Divine Intervention: A Chaotic Queer Fantasy Rom-Com-To get the promotion of their dreams, a mischievous earth-bound angel must get two ex-best friends to admit their love to each other. http://kck.st/45HvVvz JUNTOS Y FUERTES: The aim of Little Fish classes is to educate students using the standards of a traditional art school and the comic book industry with the passion and the openness of a relaxed studio environment www.lilfish.us   @littlefishcomicbooks SALUDOS: Kristian Horn @periwinklepuss www.periwinklepuss.com Follow us on socials @comadresycomics Visit our website comadresycomics.com

Reviews: Free Comic Book Day 2024 - Absolute Power, Barda, Barkham Asylum, Blood Hunt/X-Men, Dark Horse, Doctor Who, Gannibal, MAD Magazine, Marvel's Voices, Star Wars, Teenage Mutant Ninja Turtles, Ultimate Universe/Spider-Man.  Yes, we know. We're a over a month late for Free Comic Book Day comics. Apologies for that but we're here now with lots of reviews! Big focus on DC and Marvel Comics w/ a few others thrown in the mix. A lot of great teasers leading into series or graphic novels and even a fun reprint. We'll def be picking up some of the books these lead into.   Also, get a hold of us! Thanks for listening!

The avian flu outbreak is a fire drill that is showing how poorly the U.S. is prepared for the next pandemic. On the latest BioCentury This Week podcast, BioCentury's editors recap last week's BioCentury Show conversation with Rick Bright, including the former BARDA director's insights on the opportunities for biotechs to help fill voids in surveillance, point-of-care diagnostics, vaccines and therapeutics and the need for the government to provide leadership and funding to empower industry. They also discuss new SEC rules that will make reverse mergers less attractive; the Supreme Court's mifepristone ruling and a trio of neuro-focused stories -- one on FDA's guidance on presymptomatic Alzheimer's, another on an advisory committee's discussion about Eli Lilly's anti-amyloid therapy donanemab and a third focused on what neuroscience biotech companies need to consider when pitching VCs and pharmas. This week's podcast is sponsored by Nxera Pharma.0:01 - Sponsor Message: Nxera Pharma01:40 - Pandemic Prep Problems11:11 - Reverse Mergers15:43 - Alzheimer's25:31 - SCOTUS

Today we talk about Anthony Ivo, who is obsessed with immortality but probably most notable for his creation of the Amazo robot which can absorb and use super powers. Today's mentioned & relevant media: -The Brave and the Bold (1955) #30 -The Flash (1959) #158 -Action Comics (1938) #480-483 -Justice League of America (1960) #218, 258-261 -Justice League Quarterly (1990) #5 -JLA (1996) #5, 83 -Hourman (1999) #1-2 -Justice League of America (2006) #2-7, 25 -JLA: Classified (2004) #38-39, 41, 44 -Salvation Run (2007) #3 -Justice Leage: Generation Lost (2010) #11, 15, 17-19, 22-23 -Power Girl (2009) #19-20 -Supergirl (2005) #65-67 -Justice League (2011) #3, 6, 23, 23.4: Secret Society -Justice League of America (2013) #1-2, 4-5 -Justice League (2018) #13, 27 -WILDC.A.T.S (2022) #2 -Batman/Superman: World's Finest (2022) #14-15 -Star Trek: Celebrations -DC Pride 2024 -Barda by Ngozi Ukazu -X-Men: The Wedding Special (2024) #1 -The Boy Wonder (2024) #2 Thanks to Victoria Watkins for our icon! Support Capes and Japes by: Checking out our Patreon or donating to the Tip jar Find out more on the Capes and Japes website.

Today on The Prather Point LIVE at 2 pm ET / 11 am PT on RUMBLEhttps://rumble.com/v4zk2le-breaking-barda-briefs-next-bioweapon-at-bio-con.htmlMIDWAY - REAL INTEL REPLACED WITH 82 YEARS OF FAKE FAILURES!FAUCI BRIBED SCRIPPS SCIENTIST TO CALL ENGINEERED VIRUS CONSPIRACY THEORY! H5N1 = FALSE FLAG, MALAYSIAN FLU STRAIN = PLAN, & BARDA'S GOT FILLED SYRINGES!MD DR. EBEN ALEXANDER'S 7 DAY COMA, NEAR DEATH EXPERIENCE, & DIVINE ENCOUNTERS!

Jace chats with New York Times best-selling cartoonist Ngozi Ukazu about her upcoming Young Adult graphic novel BARDA. Ngozi is a self-professed life-long DC Comics fan, so it was a dream come true for her to writer and illustrate this story. Taking inspiration from the legendary Jack Kirby, Ngozi weaves a wonderful Fourth World tale starring Big Barda as she begins to question the motivations of Apocalypse and meets Scott Free for the first time. Ngozi talks about her inspirations, the fun in writing the Female Furies and so much more. Be sure to listen in and pick up the graphic novel when it drops June 4th.

FCBD Releases: Barkham Asylum, Barda, Absolute Power, Energon Universe Superman: House of Brainiac Special Blood Hunt #1 Space Ghost #1 Get Fury #1

Welcome to Comics From The Multiverse, our DC comics podcast! Discussed this week: 0:00:00 - Intro 0:12:03 - Comixology Top 10 0:21:10 - News 0:23:22 - Batman #146 (LGY #911) (Chip Zdarsky and Jorge Jimenez) 0:55:31 - Birds of Prey #8 (LGY #206) (Kelly Thompson and Javier Pina & David Lopez) 1:07:02 - Shazam #10 (Josie Campbell and Emanuela Lupacchino & Mike Norton) 1:21:11 - Poison Ivy #21 (G Willow WIlson and Marcio Takara) 1:33:34 - Blue Beetle #8 (Josh Trujillo and Adrian Guitierrez) 1:40:54 - PATREON: American Vampire Second Cycle #6 1:57:32 - Best art, cover and books of the week. patreon: https://www.patreon.com/mildfuzztv twitter: @DCComicsPodcast discord: https://discord.gg/8fbyCehMTy Audio: https://comicsfromthemultiverse.podbean.com/ Other Links: https://linktr.ee/mildfuzz

Episode 720 :  Green Arrow 9 and Birds of Prey 7: Sean and Jim jump back to some books that they haven't discussed in awhile with a focus on Oliver Queen and family in Green Arrow with an issue that has ramifications from Beast World. The guys also take a look at the new arc of Birds of Prey with the official return of an old favorite to the team. We are on Threads! https://www.threads.net/@ragingbulletspodcast Sean is a cohost on “Is it Jaws?” Check it out here : https://twotruefreaks.com/podcast/qt-series/is-it-jaws-movie-reviews/ Upcoming: Nightwing/Titans Final March Release : 18 Years of Podcasting Celebration : We are joined by longtime friend of the show Mike Gordon to discuss the first trade of Justice League International covering issues 1-7 from Giffen, DeMatteis, and Maguire. Contact Info (Social Media and Gaming) Updated 9/23: https://ragingbullets.com/about/ Facebook Group: https://www.facebook.com/groups/401332833597062/ Show Notes: 0:00 Show opening, http://www.heroinitiative.org, http://cbldf.org/,http://www.DCBService.com, http://www.Instocktrades.com, show voicemail line 1-440-388-4434 or drnorge on Skype, and more.   2:27 Birds of Prey 33:50 Green Arrow 56:50 Closing We'll be back in a week with more content.  Check our website, Twitter and our Facebook group for regular updates.

In today's episode of Med Tech Gurus, we have Mr. Wensheng Fan CEO of SpectralAI. We get into a wide-ranging conversation including how the SpectralAI team achieve a BARDA grant. We also get into how SpectralAI managed a SPAC strategy to go public. Wensheng did not stop there. We got into how SpectralAI has managed a series of pivotal studies to demonstrate their effectiveness and outcomes. Then why data integrity and quality is such an important factor for these studies and for product performance.  This is a fun and informative episode!

The Tom Renz Show – Project NextGen is (again) being run as a "national security project (DOD project with BARDA and BioDefense are all over this), so there will be zero transparency. What we do know is they are working on vaccines that can impact you if you breathe them and also vaccines that are based on saRNA (self-amplifying RNA). These lab-created RNA particles get into your system and self-replicate forever...

The Tom Renz Show – Project NextGen is (again) being run as a "national security project (DOD project with BARDA and BioDefense are all over this), so there will be zero transparency. What we do know is they are working on vaccines that can impact you if you breathe them and also vaccines that are based on saRNA (self-amplifying RNA). These lab-created RNA particles get into your system and self-replicate forever...

When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He's a guy who's deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we're getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today's episode offers a master class. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!